Loading stock data…
PHIO
$1.14-0.08 (-6.56%)
Market ClosedLast close May 1
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Phio Pharmaceuticals Corp. in the Healthcare sector is trading at $1.14. The stock is currently near its 52-week low of $0.81, remaining 28.3% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why PHIO maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.14
Potential Upside
5%
Whystock Fair Value$1.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$14.00+1128.1%
Range$14.00 – $14.00
Fundamentals
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.17%
Volume
Today's trading volume
312,670
Recent News
BC-Most Active Stocks
CCH Holdings Ltd. 18,962,694 1.32
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
Asian equities traded in the US as American depositary receipts were sharply higher Thursday morning
Phio Reports Tumor Responses in PH-762 Phase 1b Cancer Trial; Shares Surge
Phio Pharmaceuticals (PHIO) said Friday its experimental cancer therapy PH-762 showed a complete pat
Best Value Stocks to Buy for May 28th
PHIO, ALRS and URBN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 28, 2025.
New Strong Buy Stocks for May 28th
PHIO, FLNG, BWB, ALRS and HALO have been added to the Zacks Rank #1 (Strong Buy) List on May 28, 2025.